Patents by Inventor Shiang C. Gwee

Shiang C. Gwee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODY FORMULATIONS
    Publication number: 20230263895
    Abstract: The present application describes antibody formulations, including monoclonal antibodies formulated in histidine-acetate buffer, as well as a formulation comprising an antibody that binds to domain II of HER2 (for example, Pertuzumab), and a formulation comprising an antibody that binds to DR5 (for example, Apomab).
    Type: Application
    Filed: June 21, 2022
    Publication date: August 24, 2023
    Applicant: Genentech, Inc.
    Inventors: JAMES ANDYA, SHIANG C. GWEE, JUN LIU, YE SHEN
  • ANTIBODY FORMULATIONS
    Publication number: 20200179515
    Abstract: The present application describes antibody formulations, including monoclonal antibodies formulated in histidine-acetate buffer, as well as a formulation comprising an antibody that binds to domain II of HER2 (for example, Pertuzumab), and a formulation comprising an antibody that binds to DR5 (for example, Apomab).
    Type: Application
    Filed: February 7, 2020
    Publication date: June 11, 2020
    Applicant: Genentech, Inc.
    Inventors: JAMES ANDYA, SHIANG C. GWEE, JUN LIU, YE SHEN
  • ANTIBODY FORMULATIONS
    Publication number: 20180221488
    Abstract: The present application describes antibody formulations, including monoclonal antibodies formulated in histidine-acetate buffer, as well as a formulation comprising an antibody that binds to domain II of HER2 (for example, Pertuzumab), and a formulation comprising an antibody that binds to DR5 (for example, Apomab).
    Type: Application
    Filed: March 26, 2018
    Publication date: August 9, 2018
    Applicant: Genentech, Inc.
    Inventors: JAMES ANDYA, SHIANG C. GWEE, JUN LIU, YE SHEN
  • ANTIBODY FORMULATIONS
    Publication number: 20150196642
    Abstract: The present application describes antibody formulations, including monoclonal antibodies formulated in histidine-acetate buffer, as well as a formulation comprising an antibody that binds to domain II of HER2 (for example, Pertuzumab), and a formulation comprising an antibody that binds to DR5 (for example, Apomab).
    Type: Application
    Filed: March 30, 2015
    Publication date: July 16, 2015
    Applicant: GENENTECH, INC.
    Inventors: JAMES ANDYA, SHIANG C. GWEE, JUN LIU, YE SHEN
  • Method of treating cancer with a pharmaceutical formulation comprising a HER2 antibody
    Patent number: 9017671
    Abstract: The present application describes antibody formulations, including monoclonal antibodies formulated in histidine-acetate buffer, as well as a formulation comprising an antibody that binds to domain II of HER2 (for example, Pertuzumab), and a formulation comprising an antibody that binds to DR5 (for example, Apomab).
    Type: Grant
    Filed: October 25, 2012
    Date of Patent: April 28, 2015
    Assignee: Genentech, Inc.
    Inventors: James Andya, Shiang C. Gwee, Jun Liu, Ye Shen
  • Antibody formulations
    Patent number: 8372396
    Abstract: The present application describes antibody formulations, including monoclonal antibodies formulated in histidine-acetate buffer, as well as a formulation comprising an antibody that binds to domain II of HER2 (for example, Pertuzumab), and a formulation comprising an antibody that binds to DR5 (for example, Apomab).
    Type: Grant
    Filed: September 4, 2009
    Date of Patent: February 12, 2013
    Assignee: Genetech, Inc.
    Inventors: James Andya, Shiang C. Gwee, Jun Liu, Ye Shen
  • ANTIBODY FORMULATIONS
    Publication number: 20100015157
    Abstract: The present application describes antibody formulations, including monoclonal antibodies formulated in histidine-acetate buffer, as well as a formulation comprising an antibody that binds to domain II of HER2 (for example, Pertuzumab), and a formulation comprising an antibody that binds to DR5 (for example, Apomab).
    Type: Application
    Filed: September 4, 2009
    Publication date: January 21, 2010
    Applicant: Genentech, Inc.
    Inventors: James Andya, Shiang C. Gwee, Jun Liu, Ye Shen